Merck's Keytruda snags second FDA 'priority' tag this week, this time in Hodgkin's

Keytruda
U.S. regulators have handed Merck's Keytruda its second priority review distinction this week.

Merck’s Keytruda has nabbed its second FDA priority review tag of the week—and it’s one that’ll help it gain ground on archrival Opdivo from Bristol-Myers Squibb.

Thursday, the New Jersey drugmaker announced that U.S. regulators had granted the immuno-oncology star the speedy review as a treatment for patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of treatment. With the boost, Merck should have a verdict from the agency by March 15 of next year.

That means Keytruda will also get a quicker shot at challenging Opdivo in the cHL arena. Opdivo won its own indication in the disease--as a treatment for cHL patients whose disease has returned after autologous hematopoietic stem cell transplantation and post-transplantation treatment with Seattle Genetics’ Adcetris—in May, and it followed up with a European approval late last month.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Keytruda and Opdivo have been duking it out since late 2014, when they picked up their first FDA approvals in advanced melanoma. Since then, Opdivo has shot out to a lead when it comes to number of indications, but Keytruda has snagged the most lucrative of the bunch with a first-line monotherapy nod in non-small cell lung cancer.

The latest FDA action extends what was a fruitful November for both drugmakers. Earlier this week, Keytruda landed a priority distinction for the treatment of previously treated patients with advanced microsatellite instability-high cancer. And before grabbing its European cHL green light, Opdivo won the FDA’s blessing in head-and-neck cancer and posted positive phase 3 gastric cancer results.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.